KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Shares Issued (2016 - 2025)

AbbVie (ABBV) has disclosed Shares Issued for 13 consecutive years, with $48.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued rose 380.0% to $48.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $172.0 million, a 19.63% decrease, with the full-year FY2025 number at $172.0 million, down 19.63% from a year prior.
  • Shares Issued was $48.0 million for Q4 2025 at AbbVie, down from $63.0 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $128.0 million in Q1 2022 to a low of $5.0 million in Q2 2025.
  • A 5-year average of $53.6 million and a median of $54.5 million in 2022 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: skyrocketed 491.67% in 2021, then crashed 79.17% in 2024.
  • AbbVie's Shares Issued stood at $75.0 million in 2021, then fell by 29.33% to $53.0 million in 2022, then crashed by 41.51% to $31.0 million in 2023, then tumbled by 67.74% to $10.0 million in 2024, then soared by 380.0% to $48.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Shares Issued are $48.0 million (Q4 2025), $63.0 million (Q3 2025), and $5.0 million (Q2 2025).